All In Biotech

Drug Trial Radar · NCT05425602

A Study of MAX-40279combined With KN046 in Patients With Advanced / Metastatic Solid Tumors

A I / II Clinical Study to Evaluate the Safety, Tolerance, Pharmacokinetic Characteristics and Efficacy of MAX-40279 (Multi-target Tyrosine Kinase Inhibitor) Combined With KN046 (Anti-PD-L1 / CTLA-4 Bispecific Antibody) in Patients With Advanced / Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jun 21, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

108

Planned (sponsor's estimate)

Start

Jul 31, 2022

Primary completion

Dec 30, 2023

Study completion Dec 30, 2024

Sponsor

Lead sponsor
Maxinovel Pty., Ltd.Industry
Sponsor type
Industry
First posted
Jun 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This include two parts, Stage 1 is a dose climbing study and Stage 2 is a dose extending study.

Conditions

  • Advanced / Metastatic Solid Tumors

Interventions

  • MAX-40279-01: 50mg/70mgDrug

    \[Stage 1\]The starting dose of MAX-40279 was 35 mg BID, and three dose levels were initially set: 35 mg, 50 mg, and 70 mg administered twice daily (BID) continuously, and the dose of KN046 was 5 mg/kg as a fixed dose administered every 3 weeks. \[Stage 2\]When the RP2D dose is obtained in the dose-finding phase, the trial will enter the dose expansion phase.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DLTTime frame: through study Stage1 completion,an average of 6 months
  2. Maximum Tolerated Dose (MTD) or Recommended Phase 2 Dose (RP2D)Time frame: through study Stage1 completion,an average of 6 months
  3. ORRTime frame: through study Stage2 completion,an average of 24 months
  4. PFSTime frame: through study Stage2 completion,an average of 24 months
  5. Adverse events (AEs), serious adverse events (SAEs)Time frame: through study Stage2 completion,an average of 24 months
  6. laboratory testsTime frame: through study Stage2 completion,an average of 24 months
  7. vital signsTime frame: through study Stage2 completion,an average of 24 months
  8. 12 ECGTime frame: through study Stage2 completion,an average of 24 months
  9. physical examination abnormalitiesTime frame: through study Stage2 completion,an average of 24 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.